Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis

Immunopharmacology and Immunotoxicology

Volumn 29, Issue 1, 2007, Pages 49-61

  Mirshafiey, A ^a   Rehm, B ^b   Sotoude, M ^a   Razavi, A ^a   Abhari, R Safari ^a   Borzooy, Z ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

Anti Inflammatory; Glomerulonephritis; M2000; NSAIDs; Proteinuria

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; BOVINE SERUM ALBUMIN; CHOLESTEROL; CREATININE; DEXAMETHASONE; DICLOFENAC; GELATINASE A; M 2000; MANNURONIC ACID; PIROXICAM; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS; HISTOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNE COMPLEX NEPHRITIS; IMMUNIZATION; IMMUNOFLUORESCENCE; KIDNEY PARENCHYMA; LYMPHOCYTIC INFILTRATION; MICROSCOPY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ZYMOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGEN-ANTIBODY COMPLEX; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; GLOMERULONEPHRITIS; HEXURONIC ACIDS; MATRIX METALLOPROTEINASE 2; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE;

ANIMALIA; BOVINAE; RATTUS;

EID: 34247622280     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970701282387     Document Type: Article

References (29)

1. Quigg, R.J. Complement and autoimmune glomerular diseases. Curr. Dir. Autoimmun. 2004, 7, 165-180.
2. Vinen, C.S.; Oliveira, D.B.G. Acute glomerulonephritis. Postgrad. Med. J. 2003, 79, 206-213.
3. Tarzi, R.M.; Cook, H.T. Role of Fcgamma receptors in glomerulonephritis. Nephron Exp. Nephrol. 2003, 95, e7-12.
4. Rougier, J.P.; Ronco, P. Pathogenesis of immune glomerulonephritis. Rev. Prat. 2003, 53, 1998-2004.
5. Hricik, D.E.; Chung-park, M.; Sedor, J.R. Glomerulonephritis. N. Engl. J. Med. 1998, 339, 888-899.
6. Camp, T.M.; Smiley, L.M.; Hayden, M.R.; Tyagi, S.C. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J. Hypertens. 2003, 21, 1719-1727.
7. Sanders, J.S.; van Goor, H.; Hanemaaijer, R.; Kallenberg, C.G.; Stegeman, C.A. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 2004, 19, 1412-1419.
8. Zhang, Z.G.; Liu, X.G.; Chen, G.P.; Zhang, X.R.; Guo. M.Y. Significance of MMP-2 and TIMP-2 mRNA expressions on glomerular cells in the development of glomerulosclerosis. Med. Sci. J. 2004, 19, 84-88.
9. Mirshafiey, A.; Rehm, B.H.; Sahmani, A.A.; Naji, A.; Razavi, A. M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis. Immunopharmacol. Immunotoxicol. 2004, 26, 611-619.
10. Mirshafiey, A.; Matsuo, H.; Nakane, S.; Rehm, B.H.; Koh, C.S.; Miyoshi, S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol. Immunotoxicol. 2005, 27, 255-265.
11. Mirshafiey, A.; Cuzzocrea, S.; Rehm, B.; Mazzon, E.; Saadat, F.; Sotoude, M. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand. J. Immunol. 2005, 61, 435-441.
12. Yamamoto, T.; Kihara, I.; Morita, T.; Oite, T. Bovine serum albumin (BSA) nephritis in rats: I Experimental model. Acta. Pathol. Jpn. 1978, 28, 859-860.
13. Hogendoorn, P.C.W.; Bruijn, J.A.; Gelok, E.W.A.; Van Den Broek, L.J.C.M.; Fleuren, G.J. Development of progressive glomerulosclerosis in experimental chronic serum sickness. Nephrol. Dial. Transplant. 1990, 5, 100-109.
14. Bousnes, R.W.; Taussky, A.A. The calorimetric determination of creatinine by the Jaffe reaction. J. Biol. Chem. 1945, 158, 581-591.
15. Evans, R.T. Manual and automated methods for measuring urea based on a modification of its reaction with diacetyl monoxime and thiosemicarbazide. J. Clin. Pathol. 1968, 2, 527-532.
16. Heussen, C.; Dowdle, E.B. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Analytical Biochemistry. 1980, 102, 196-202.
17. Cattran, D.C. Outcomes research in glomerulonephritis. Semin. Nephrol. 2003, 23, 340-354.
18. O'Callaghan, C.A. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract. Res. Clin. Rheumatol. 2004, 18, 411-427.
19. Fogo, A.B.; Quiz, page. Acute interstitial nephritis and minimal change disease lesion, caused by NSAIDS injury. Am. J. Kidney Dis. 2003, 42, A41-E1.
20. Reinhold, S.W.; Fischereder, M.; Riegger, G.A.; Kramer, B.K. Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor. Clin. Nephrol. 2003, 60, 295-296.
21. Basivireddy, J.; Jacob, M.; Pulimood, A.B.; Balasubramanian, K.A. Indomethacin-induced renal damage: role of oxygen free radicals. Biochem. Pharmacol. 2004, 67, 587-599.
22. Stollbergen, C.; Finsterer, J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med. J. 2004, 97, 209-209.
23. Perazella, M.A. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am. J. Med. Sci. 2003, 325, 349-362.
24. Kaiser, A. Diclofenac caused renal insufficiency. A case illustrating the necessity of pharmaceutical intervention and care. Med. Monatsschr. Pharm. 2003, 26, 384-388.
25. Lenz, O.; Elliot, S.J.; Stetler-Stevenson, W.G. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 2000, 11, 574-581.
26. Chadban, S. Glomerulonephritis recurrence in the renal graft. J. Am. Soc. Nephrol. 2001, 12, 394-402.
27. Marti, H.P. The role of matrix metalloproteinases in the activation of mesangial cells. Transpl. Immunol. 2002, 9, 97-100.
28. Lovett, D.H.; Johnson, R.J.; Marti, H.P.; Martin, J.; Davies, M.; Couser, W.G. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am. J. Pathol. 1992, 141, 85-98.
29. Harendza, S.; Schneider, A.; Helmchen, U.; Stahl, R.A. Extracellular matrix deposition and cell proliferation in a model of chronic glomerulonephritis in the rat. Nephrol. Dial. Transplant. 1999, 12, 2873-2879.